| 000 | 00952 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517093149.0 | ||
| 264 | 0 | _c20190610 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a2352-3026 | ||
| 024 | 7 |
_a10.1016/S2352-3026(16)30021-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchiff, David | |
| 245 | 0 | 0 |
_aDefining optimal initial therapy for primary CNS lymphoma. _h[electronic resource] |
| 260 |
_bThe Lancet. Haematology _c05 2016 |
||
| 300 |
_ae206-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aCentral Nervous System Neoplasms |
| 650 | 0 | 4 | _aCytarabine |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMethotrexate |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aThiotepa |
| 700 | 1 | _aHong, Fangxin | |
| 700 | 1 | _aAlexander, Brian | |
| 773 | 0 |
_tThe Lancet. Haematology _gvol. 3 _gno. 5 _gp. e206-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2352-3026(16)30021-7 _zAvailable from publisher's website |
| 999 |
_c25975787 _d25975787 |
||